Your email and its content will be used to provide you an answerto your message. You have the possibility to access, to modify, to rectify and to suppress any personal data concerning you.
To exercise this right, please click here.
Ipsen at a glance
The group in 2015
27 September 2016 - Paris (France)
Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the…